Assessing Patterns and Treatment Outcomes in HER-2 Positive Metastatic Breast Cancer Patients With Brain Metastases

A novel study aimed to assess the real-world treatment patterns and clinical outcomes of HER+ breast cancer-related brain metastases. The findings were presented at the 2024 San Antonio Breast Cancer Symposium.

This single institution retrospective study included 78 HER2+ MBC patients with BMs treated between Jan 2017 – Feb 2024, all with at least six months of follow-up after BM diagnosis. In this study, overall survival (OS) was defined from date of BM diagnosis to date of death, while systemic progression-free survival (PFS) and CNS-PFS were defined from systemic therapy initiation date to systemic or CNS disease progression, respectively. The investigators used the Kaplan-Meier method was to analyze survival.

According to the findings, the combination of SRS and HER2 targeted systemic therapies resulted in robust survival outcomes but some risk of RN. Interestingly, the researchers noted, TUC trended toward a longer treatment duration than T-DM1 or T-DXd. “Further investigation into reasons for discontinuation of each systemic therapy (toxicity vs. progression) is warranted,” the researchers concluded.

Reference

Mestres-Villanueva M, Gokum Y, Daniel S, et al. Real World Treatment Patterns and Outcomes in Her-2 Positive
Metastatic Breast Cancer Patients with Brain Metastases. Abstract #SESS-2008. Presented at the 2024 San Antonio Breast Cancer Symposium; December 10-13, San Antonio, Texas.